Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas. [electronic resource]
Producer: 20160909Description: 3071-81 p. digitalISSN:- 1029-2403
- Adult
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Busulfan -- administration & dosage
- Carmustine -- therapeutic use
- Cytarabine -- therapeutic use
- Female
- Follow-Up Studies
- Hematopoietic Stem Cell Transplantation -- adverse effects
- Hodgkin Disease -- mortality
- Humans
- Lymphoma, Non-Hodgkin -- mortality
- Male
- Matched-Pair Analysis
- Melphalan -- therapeutic use
- Middle Aged
- Neoplasm Staging
- Podophyllotoxin -- therapeutic use
- Retrospective Studies
- Survival Analysis
- Transplantation Conditioning
- Transplantation, Autologous
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.